FDA Issues Public Health Advisory and Warning for Strattera

FDA Alert [09/05]: Suicidal Thinking in Children and Adolescents

The Food and Drug Administration directed Eli Lilly to revise the labeling for Strattera to include a boxed warning and additional warning statements regarding an increased risk of suicidal thinking in children and adolescents being treated with this drug. For more information visit the FDA website.

For more information from the manufacturer, visit the Lilly website.